Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatment, and preliminary evidence of efficacy of the scheduled drug for the particular condition. Since 2014, the authors have obtained 50 licenses on a case-by-case basis and developed a psychedelic-assisted group therapy model utilizing MDMA and LSD. The majority of the patients taking part in the psychedelic group therapy suffered from chronic complex post-traumatic stress disorder (c-PTSD), dissociative, and other post-traumatic disorders. Treatment modalities, typical developments and problems encountered during and after the psychedelic experiences are described. Recurrent depression poses a frequent problem, and requires special attention. Symptoms of c-PTSD predominantly addressed by the psychedelic experiences are the regulation of emotions and impulses, negative self-perception, alterations in relationships to others, as well as meaning, recall, and processing of traumatic memories. C-PTSD needs a larger number of psychedelic experiences in contrast to PTSD resulting from single trauma. In this model MDMA was most often used in the first phase to enhance motivation to change, strengthen the therapeutic alliance, allowing it to become more resilient, stress-relieved and less ambivalent. When emotional self-regulation, negative self-perception and structural dissociation had also begun to improve and trauma exposure was better tolerated, LSD was introduced to intensify and deepen the therapeutic process. The majority of participants improved by clinical judgement, and no serious adverse events occurred. A short case vignette describes a typical process. The experiences with this model can serve to further develop the method of psychedelic-assisted psychotherapy (PAP) and to give directions for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05710-w · Cited by 40 · cited 1×
“On one hand, short-term tapering as we used in our method, has been shown to diminish response to MDMA-assisted therapy (36).”
MethodRetractedComplex PTSD: A syndrome in survivors of prolonged and repeated trauma
Herman, J. L. (1992) · Journal of Traumatic Stress · doi:10.1002/jts.2490050305 · Cited by 2,609 · cited 1×
“It describes in a coherent and integrative way the multifaceted symptoms of traumatized patients who suffered repeated or prolonged physical, sexual and/or emotional abuse and neglect during childhood and adolescence, often by close caregivers, where escape was not possible due to physical, developmental or environmen…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“Trauma-related disorders: PTSD/c-PTSD/Dissociative Disorder - with comorbid depression - with comorbid borderline personality traits - with comorbid personality disorder 6 (23%) - (5) - (1) - (1) 15 (63%) - (7) - (3) - (0) 21 (46%) - (12) - (4) - (1)”
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“Trauma-related disorders: PTSD/c-PTSD/Dissociative Disorder - with comorbid depression - with comorbid borderline personality traits - with comorbid personality disorder 6 (23%) - (5) - (1) - (1) 15 (63%) - (7) - (3) - (0) 21 (46%) - (12) - (4) - (1)”
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 1×
“After the Swiss MDMA/PTSD study and the Swiss LSD/anxiety in life-threatening disease study results were published in 2013 and 2014 (6, 15) the principal investigators of these two studies were able to obtain licenses from the Swiss FOPH for the administration of LSD and MDMA to patients from their own patient pools i…”
BackgroundSelf-citation
Cited by
History repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137
“…risks include the destabilizing effects that psychedelics can have through the experiences they can trigger, which can be difficult to handle both for the person and their therapist 58 – experiences that can result to everything from increased acute agitation to prolonged emotional dysregulation.”
BackgroundLower-dose psycholytic therapy – A neglected approach
Passie, T., Guss, J., & Krähenmann, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1020505 · Cited by 81
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82
MDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Stocker, K., & Liechti, M. E. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265352 · Cited by 19
“…a sense of connection that is situated within the here-and-now and/or within the autobio-graphical realm without wanting to enter transpersonal or potentially more confrontational realms, then MDMA might be the first connectogen of choice for such therapeutic goals (cf. Oehen and Gasser, 2022).”
Background
Metadata
- Authors
- Oehen, P., & Gasser, P.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2022-04-25
- Volume
- 13
- Pages
- 863552-863552
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W4224443490
- Cited by
- 73
- References
- 18
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders. https://app.cochat.ai/papers/10.3389/fpsyt.2022.863552
- The paper
- Oehen, P., & Gasser, P. (2022). Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.863552
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.